27 November 2018 - The first children to receive Novartis’ Kymriah – a ‘game-changing’ CAR-T therapy for cancer - will start treatment at Great Ormond Street Hospital in London this week, NHS England has announced.

A second centre, Royal Manchester Children’s Hospital, is also ready to begin treating children with a rare form of leukaemia with Kymriah (tisagenlecleucel) while a third, Newcastle upon Tyne Hospitals NHS Foundation Trust, is expected to join the programme next month.

The start of this treatment, which costs around £282,000 per patient at its full list price, “marks the beginning of a new era of personalised medicine, and forms part of the upgrade in cancer services which will be set out shortly NHS’s long term plan,” NHS England said.

Read Pharma Times article